159 related articles for article (PubMed ID: 12573174)
1. Evaluating acute effects of potential reduced-exposure products for smokers: clinical laboratory methodology.
Breland AB; Buchhalter AR; Evans SE; Eissenberg T
Nicotine Tob Res; 2002; 4 Suppl 2():S131-40. PubMed ID: 12573174
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes.
Buchhalter AR; Schrinel L; Eissenberg T
Nicotine Tob Res; 2001 May; 3(2):111-8. PubMed ID: 11403724
[TBL] [Abstract][Full Text] [Related]
3. Clinical laboratory evaluation of potential reduced exposure products for smokers.
Breland AB; Kleykamp BA; Eissenberg T
Nicotine Tob Res; 2006 Dec; 8(6):727-38. PubMed ID: 17132520
[TBL] [Abstract][Full Text] [Related]
4. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking.
Lee EM; Malson JL; Moolchan ET; Pickworth WB
Nicotine Tob Res; 2004 Feb; 6(1):95-102. PubMed ID: 14982693
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting.
Fagerström KO; Hughes JR; Callas PW
Nicotine Tob Res; 2002; 4 Suppl 2():S141-5. PubMed ID: 12573175
[TBL] [Abstract][Full Text] [Related]
6. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure.
Strasser AA; Lerman C; Sanborn PM; Pickworth WB; Feldman EA
Drug Alcohol Depend; 2007 Jan; 86(2-3):294-300. PubMed ID: 16930853
[TBL] [Abstract][Full Text] [Related]
7. Changes in markers of epithelial permeability and inflammation in chronic smokers switching to a nonburning tobacco device (Eclipse).
Stewart JC; Hyde RW; Boscia J; Chow MY; O'Mara RE; Perillo I; Pietropaoli A; Smith CJ; Torres A; Utell MJ; Frampton MW
Nicotine Tob Res; 2006 Dec; 8(6):773-83. PubMed ID: 17132525
[TBL] [Abstract][Full Text] [Related]
8. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes.
Buchhalter AR; Acosta MC; Evans SE; Breland AB; Eissenberg T
Addiction; 2005 Apr; 100(4):550-9. PubMed ID: 15784070
[TBL] [Abstract][Full Text] [Related]
9. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications.
Pederson LL; Nelson DE
Nicotine Tob Res; 2007 May; 9(5):525-34. PubMed ID: 17454709
[TBL] [Abstract][Full Text] [Related]
10. Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings?
Rezaishiraz H; Hyland A; Mahoney MC; O'Connor RJ; Cummings KM
Nicotine Tob Res; 2007 Nov; 9(11):1139-46. PubMed ID: 17978987
[TBL] [Abstract][Full Text] [Related]
11. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review.
Fagerström KO; Hughes JR
Nicotine Tob Res; 2002; 4 Suppl 2():S73-9. PubMed ID: 12573169
[TBL] [Abstract][Full Text] [Related]
12. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette.
Benowitz NL; Hall SM; Stewart S; Wilson M; Dempsey D; Jacob P
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2479-85. PubMed ID: 18006940
[TBL] [Abstract][Full Text] [Related]
13. Smoking topography in response to denicotinized and high-yield nicotine cigarettes in adolescent smokers.
Kassel JD; Greenstein JE; Evatt DP; Wardle MC; Yates MC; Veilleux JC; Eissenberg T
J Adolesc Health; 2007 Jan; 40(1):54-60. PubMed ID: 17185206
[TBL] [Abstract][Full Text] [Related]
14. Harm reduction policies for tobacco users.
Gartner C; Hall W
Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO; Weaver MF; Eissenberg T
Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
[TBL] [Abstract][Full Text] [Related]
16. [Smoking reduction and temporary abstinence: new approaches for smoking cessation].
Le Houezec J; Säwe U
J Mal Vasc; 2003 Dec; 28(5):293-300. PubMed ID: 14978435
[TBL] [Abstract][Full Text] [Related]
17. Human cigarette smoking: effects of puff and inhalation parameters on smoke exposure.
Zacny JP; Stitzer ML; Brown FJ; Yingling JE; Griffiths RR
J Pharmacol Exp Ther; 1987 Feb; 240(2):554-64. PubMed ID: 3806411
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of Advance: a potential reduced exposure product for smokers.
Breland AB; Evans SE; Buchhalter AR; Eissenberg T
Tob Control; 2002 Dec; 11(4):376-8. PubMed ID: 12432165
[TBL] [Abstract][Full Text] [Related]
19. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments.
Rose JE; Behm FM
Nicotine Tob Res; 2004 Jun; 6(3):523-32. PubMed ID: 15203786
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of tobacco industry retail marketing activities of reduced harm products.
Slater S; Giovino G; Chaloupka F
Nicotine Tob Res; 2008 Jan; 10(1):187-93. PubMed ID: 18188759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
